Abuse-Deterrent Opioid Formulations in Pain Management Decisions: Is Now the Time?
Pre-Activity Survey

Question Title

1. The act of selling an opioid prescription to another individual is best described as opioid:

Abuse

Misuse

Diversion

Manipulation

Question Title

2. The most common route of opioid abuse among teens and adolescents is:

Inhalation

Ingestion

Injection

Smoking

Question Title

3. All of the following opioid formulations utilize primarily a physical/chemical barrier to inhibit opioid abuse except:

OxyContin®

Targiniq®

Ventrela®

Hysingla®

Question Title

4. Current abuse-deterrent technologies CANNOT prevent:

Ingestion of supratherapeutic doses on non-manipulated product

Crushing of tablets to fine powder for snorting

Dissolving the opioid to be drawn into a syringe for injection

Extraction of the opioid by water or alcohol

Question Title

5. An opioid antagonist that is used in abuse-deterrent formulations is:

Naltrexone

Disulfiram

Acamprosate

Buproprion

Question Title

6. All abuse-deterrent formulations currently available are extended release:

True

False

Question Title

7. Abuse-deterrent is same as abuse-proof:

True

False